Evaluation of BD Glucan in Peritoneal Fluid for the Diagnosis of Fungal Peritonitis (PERICAND)

Civil Hospices of Lyon

Status: Completed

Conditions: Adult Patient (Over 18 Yr-old) Admitted to the ICU for Acute Peritonitis

Treatments: Other: Intervention

Study type: Observational

Funder types: Other

Identifiers

NCT03469401

69HCL17_0775

Details and patient eligibility

About

Invasive candidiasis has a high mortality rate, around 40%. Outcome remains tightly linked to the time of treatment administration. Routine microbiological techniques give results too lately to allow prompt antifungal therapy initiation (at least 48 hours). It is important to develop diagnostic tools to initiate antifungal therapy as early as possible.

The B D glucan detection, one of the major components of the candida cell wall, can be useful for a early diagnosis.

There are several techniques on the market for the detection of glucan. In Europe and America, the most used is Fungitell (Associated of Cape Cod, Inc).

There is several studies about the use of such kits for fungemia. A number of studies are reporting evidences of a early diagnosis.

But, in medical literature, there isn't study focused on the detection of B D glucan in peritoneal fluid for Candida peritonitis diagnosis.

Enrollment: 126 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Aged ≥ 18 years old
• written informed consent for inclusion in the study
• stay in intensive care unit
• diagnosed with a peritonitis
• peritoneal fluid collected by a surgery or radiology procedure, analysed at bacteriology laboratory of l'institut des agents infectieux, l'hôpital de la Croix Rousse

Exclusion criteria

• Pregnant woman
• Moribund patient

Trial design

126 participants in 1 patient group

intervention

Description:

Adult patient (over 18 yr-old) admitted to the ICU for acute peritonitis with a peritoneal fl:uid sample obtained via surgery or radiological drainage

Treatment:

Other: Intervention